Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients.

Man-Fung YuenWan-Long ChuangCheng-Yuan PengWen-Juei JengWei-Wen SuTing-Tsung ChangChi-Yi ChenYao-Chun HsuGuy De La RosaAlaa AhmadEd LuoAnnie L Conery

Published in: Clinical and molecular hepatology (2024)

In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.

Keyphrases

end stage renal disease
hepatitis b virus
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
physical activity
liver fibrosis